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We have shown previously that near-infrared light (NIr) treatment or photobiomodulation neuroprotects dopaminergic cells in
substantia nigra pars compacta (SNc) from degeneration induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in
mice. The present study explores whether NIr treatment changes the patterns of Fos expression in the subthalamic region, namely,
the subthalamic nucleus (STN) and zona incerta (ZI); both cell groups have abnormally overactive cells in parkinsonian cases.
BALB/c mice were treated with MPTP (100–250mg/kg) or saline either over 30 hours followed by either a two-hour or six-day
survival period (acute model) or over ﬁve weeks followed by a three-week survival period (chronic model). NIr and MPTP were
applied simultaneously. Brains were processed for Fos immunochemistry, and cell number was estimated using stereology. Our
major ﬁnding was that NIr treatment reduced (30–45%) the increase in Fos+ cell number evident in the STN and ZI after MPTP
insult. This reduction was concurrent with the neuroprotection of dopaminergic SNc cells shown previously and was evident in
both MPTP models (except for the 2 hours survival period which showed no changes in cell number). In summary, our results
indicated that NIr had long lasting eﬀects on the activity of cells located deep in the brain and had repaired partially the abnormal
activity generated by the parkinsonian toxin.
1.Introduction
Exposuretonear-infraredlighttreatment(NIr),alsoreferred
to as photobiomodulation, has been shown to protect do-
paminergic cells from degeneration induced by 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) in both in vitro
[2, 3]a n din vivo (within substantia nigra pars compacta;
SNc) [4, 5] studies. This neuroprotection is presumably due
to the NIr limiting the mitochondrial dysfunction and sub-
sequent oxidative stress and free-radical production caused
by the MPTP, which induces Parkinson-like pathology [4,
6]. NIr has been shown to improve mitochondrial func-
tion and ATP (adenosine-5 -triphosphate) production by
increasing the electron transfer in the respiratory chain and
activation of photoacceptors, such as cytochrome oxidase
[7, 8]. Although these results are from in vitro studies [2,
3] and from an animal model of the disease [4, 5], the
outcome is potentially exciting; that a noninvasive procedure
oﬀers neuroprotection in Parkinson’s disease, a feature that
most current forms of treatment, including dopamine-re-
placement drug therapy, does not do [9].
I nt h i ss t u d y ,w eh a v es o u g h tt oe x t e n do u re a r l i e ra n -
atomical ﬁndings [4, 5] by examining patterns of cell ac-
tivation associated with the neuroprotective action of NIr
in parkinsonian cases. To this end, we examined cell activity2 Parkinson’s Disease
in the subthalamic region, namely, the subthalamic nucleus
(STN)andthezonaincerta(ZI).Wechosethisregionfortwo
mainreasons(i)STNandZIcellshaveabnormaloveractivity
in parkinsonian cases [10–13] and (ii) both cell groups
have become a popular targets for surgical intervention,
particularly with deep brain stimulation [14–16]. It is well
accepted that an increase in Fos expression, after activation
of the cFos gene, reﬂects an increase in cell activity. This
method has been used to study global cell activity patterns
in many brain regions after various forms of stimulation and
disease states, including parkinsonism [17, 18]. In essence,
we tested whether NIr treatment was able to inﬂuence the
activity of cells located deep in the brain and reverse the
abnormal activity induced by the parkinsonian insult.
2.MaterialsandMethods
2.1.Subjects. MalealbinoBALB/cmice(∼20g; ∼8-weekold;
n = 96) were housed on a 12 hours light/dark cycle with un-
limited access to food and water. All experiments were
approved by the Animal Ethics Committee of The University
of Sydney.
2.2. Experimental Design. An acute [4, 19] and a chronic
[5] MPTP model were used in this study. There were four
experimental groups in each model, where mice received
intraperitoneal injections of either MPTP or saline, com-
binedwithsimultaneousNIrtreatmentsornot.Thediﬀerent
groupswere(1)saline(n = 24):salineinjectionswithnoNIr,
(2) saline-NIr (n = 24): saline injections with NIr, (3) MPTP
(n = 24): MPTP injections with no NIr, and (4) MPTP-NIr
(n = 24): MPTP injections with NIr.
For the acute model, four (25mg/kg injections; total of
100mg/kg per mouse) MPTP or saline injections were made
over a 30-hour period. After the last injection, mice were
allowed to survive for either two hours (n = 32) or six
days (n = 32). For the chronic model (n = 32), mice
had ten injections of MPTP (20mg/kg per injection; total of
200mg/kg per mouse) or saline combined with probenecid
(250mg/kg; decreases renal excretion of MPTP and hence
maintains the eﬀects of toxin during injection intervals)
approximately three and a half days apart, over a ﬁve-week
period. After the last injection, mice were allowed to survive
for three weeks. For both models, the dose regimes and
survival periods were the same as those used by previous
studies [4, 5, 19] .T h es u r v i v a lp e r i o d sw e r es e l e c t e da s
to determine whether there were any immediate or longer
lasting changes in Fos expression after MPTP (or NIr)
treatment.
For the NIr treatment, mice in the MPTP-NIr and saline-
NIr groups of each model (acute and chronic) were treated
with 670nm light from a light-emitting device (LED;
Quantum Devices WARP 10) as described previously [4, 5].
Brieﬂy, mice had NIr treatment (one cycle of 90 seconds;
estimated at 0.5Joule/cm2 to the brain [4]) for ∼15 minutes
after each MPTP or saline injection. Hence, for each MPTP
insulttherewouldbealmostimmediatepotentialtherapeutic
application. For both models, these NIr treatment regimes
were similar to that used by previous studies, in particular,
those reporting changes after transcranial irradiation [4, 5,
20, 21]. For each exposure to NIr, the mouse was restrained
gently by hand, and the LED was held 1-2cm above the
head [4, 5]. The mice tended to relax during exposure, and
reliable delivery of the radiation was achieved readily. The
LED generated very little heat and it did not cause the mice
any visible discomfort. For the saline and MPTP groups,
mice were held under the LED as described above for 90
seconds, but the device was not turned on [4, 5].
Our experimental paradigm, of essentially simultane-
ous administration of parkinsonian insult and therapeutic
application, was similar to that of many previous studies
on animal models of Parkinsons disease [4, 5, 19, 22].
This paradigm is unlike the clinical reality where consid-
erable dopaminergic cell loss occurs prior to therapeutic
intervention. However, in our experimental study—as with
the abovementioned previous ones—we hoped to explore
the maximum eﬀect of NIr treatment on the number of
dopaminergic cells and hence determine more systematically
its eﬀects on functional activity (i.e., Fos expression).
2.3. Immunocytochemistry. Following the survival periods,
mice were anaesthetised with an intraperitoneal injection of
sodium pentobarbital (60mg/mL). They were then perfused
transcardially with 0.1M phosphate-buﬀered saline (PBS;
pH 7.4), followed by 4% buﬀered formaldehyde. The brains
were removed and postﬁxed overnight in the same solution.
Next, brains were placed in PBS with the addition of
30% sucrose until the block sank. The forebrain was then
sectioned coronally and serially using a freezing microtome.
All sections were collected in PBS and then immersed in a
solution of 1% Triton (Sigma) and 10% normal goat serum
(Sigma) at room temperature for 30 minutes each. Sections
were then incubated in anti-cFos (SantaCruz; 1:4000) for 48
hours(at4◦C),followedbybiotinylatedanti-rabbitIgG(Bio-
scientiﬁc;1:200)forthreehours(atroomtemperature),and
then streptavidin-peroxidase complex (Bioscientiﬁc; 1:200)
for two hours (at room temperature). To visualise the bound
antibody, sections were reacted in nickel-Tris-buﬀered saline
(pH 7.4)-3,3 -diaminobenzidine tetrahydrochloride (Sigma)
solution. In between incubations, sections were washed in
three changes of PBS. Sections were mounted onto gela-
tinised slides, air dried overnight, dehydrated in ascending
alcohols, cleared in Histoclear, and coverslipped using DPX.
Most of our immunostained sections were counterstained
lightly with neutral red as well. For controls, sections were
processed as described above, except that there was no
primary antibody used. These control sections were im-
munonegative.
2.4. Analysis. Following the procedures outlined by previous
studies [4, 5, 19], the number of Fos+ cells within the
STN and ZI were estimated using the optical fraction-
ator method (StereoInvestigator, MBF Science). Brieﬂy,
systematic random sampling of sites within deﬁned bound-
aries of the STN and ZI was undertaken. All cells
that came into focus within the frame were counted.Parkinson’s Disease 3
Figures 4(e) and 5(e) show schematic diagrams of the mouse
brain, and the shaded areas indicate the general regions that
were analysed. The distribution maps of Fos+ cells (Figures
4(a)–4(d), 5(a)–5(d)) were constructed using the StereoIn-
vestigatorprogrammealso.Forcomparisonsbetweengroups
within each model (six-day survival and two-hour survival
acute model and chronic model), a one-way ANOVA test
(F and P values) was performed, in conjunction with a
Tukey-Kramer multiple comparison test (q and P values)
(using GraphPad Prism programme). Schematic diagrams
and digital images were constructed using Adobe Photoshop
and Microsoft PowerPoint programmes.
3. Results
In what follows, the morphology, number, and distribution
of Fos+ cells in the STN and ZI will be considered separately.
3.1. Morphology. In both the STN and ZI, Fos immunore-
activity was limited to the nuclei of cells (Figure 1). The
intensity of immunoreactivity was not consistent across
both cell groups; cells were immunostained either strongly
(arrows, Figure 1) or weakly (arrowheads, Figure 1). These
patterns were evident across the STN (Figures 1(a) and 1(b))
and in each of the diﬀerent sectors of the ZI, namely, rostral
(Figure 1(c)), dorsal (Figure 1(d)), ventral (Figure 1(e)), and
caudal (Figure 1(f)) and were similar in all the experimental
groups of both acute and chronic MPTP models.
3.2. Number. In this study, we counted the number of Fos+
cells in the STN and ZI that were immunostained strongly
(see above), presumably because they had undergone the
most activation [17, 23]. The number of cells in the STN and
ZI in the acute and chronic MPTP models will be considered
separately below.
3.2.1. Subthalamic Nucleus (STN). The graph in Figure 2(b)
shows the estimated number of Fos+ cells in the STN of
the four experimental groups in the acute MPTP model.
In the two-hour survival period, there were 50–60% more
Fos+ cells in the saline-NIr, MPTP, and MPTP-NIr groups
than in the saline group. Overall, using an ANOVA test,
these diﬀerences were signiﬁcant (F = 6.2; P<0.001).
Using the Tukey-Kramer test, signiﬁcant diﬀerences in total
number were found between the saline group and the saline-
NIr (q = 4.0; P<0.05), MPTP (q = 4.1; P<0.05),
and MPTP-NIr (q = 5.9; P<0.01) groups. There were no
signiﬁcant diﬀerences between the saline-NIr group and the
MPTP (q = 0.1; P>0.05) or MPTP-NIr (q = 1.9; P>
0.05) groups, nor between the MPTP and MPTP-NIr groups
(q = 1.8; P>0.05). In the six-day survival period, the MPTP
grouphadmoreFos+ cellsthantheMPTP-NIr(40%),saline-
NIr (80%), and saline (85%) groups. Of particular relevance
was that the MPTP-NIr group had fewer Fos+ cells than the
MPTP group, indicating that NIr treatment had reduced the
Fos expression induced by the MPTP insult. Further, the
MPTP-NIr group had more Fos+ cells than the saline groups
(65–75%), indicating that although there was a reduction in
number from the MPTP insult, it did not quite reach control
levels. Overall, these diﬀerences between the groups were
signiﬁcant using an ANOVA test (F = 65.7; P<0.0001).
Using the Tukey-Kramer test, signiﬁcant diﬀerences in total
number were found between the MPTP group and saline
(q = 17.6; P<0.001), saline-NIr (q = 16.0; P<0.001), and,
notably, MPTP-NIr (q = 8.1; P<0.001) groups. There were
alsosigniﬁcantdiﬀerencesbetweentheMPTP-NIrgroupand
saline (q = 9.5; P<0.001) and saline-NIr (q = 7.9; P<
0.001) groups. The diﬀerences in total number between the
saline and saline-NIr groups were not signiﬁcant (q = 1.6;
P>0.05).
The graph in Figure 2(b) shows the estimated number
of Fos+ cells in the STN of the four groups in the chronic
MPTP model. The patterns of Fos+ cell number shown for
this model were similar to those described above for the six-
day survival acute model. The MPTP group had more Fos+
cellsthantheMPTP-NIr(45%),saline-NIr(75%),andsaline
(75%) groups. The MPTP-NIr group had fewer Fos+ cells
than the MPTP group but many more cells than in the saline
groups (55%). Overall, these diﬀerences between the groups
weresigniﬁcantusinganANOVAtest(F = 34.2;P<0.0001).
Using the Tukey-Kramer test, signiﬁcant diﬀerences in total
number were found between the MPTP group and saline
(q = 12.4; P<0.001), saline-NIr (q = 12.3; P<0.001),
and MPTP-NIr (q = 7.1; P<0.001) groups. There were also
signiﬁcant diﬀerences between the MPTP-NIr group and the
saline (q = 5.4; P<0.01) and saline-NIr (q = 5.2; P<0.01)
groups. The diﬀerences in total number between the saline
and saline-NIr groups were not signiﬁcant (q = 0.2; P>
0.05).
It should be noted that the number of tyrosine hydrox-
ylase (TH)+ cells in the substantia nigra pars compacta
(SNc), from the same brains from as those used here for
Fos immunocytochemistry, have been analysed also, and full
details of the results have been published [4, 5]. Brieﬂy,
these studies showed substantial TH+ cell loss in the SNc
in both acute (∼60%, six-day survival; no change in TH+
cell number in two-hour survival period) and chronic (∼
45%) MPTP models. In addition, there was also fewer TH+
terminals in the striatum, the major termination zone of the
SNc axons, of the MPTP groups compared to the others.
Finally,theMPTP-NIrgroupsofbothmodelshadmoreTH+
cells than in the MPTP group (30–35%) but not quite as
many as in the saline control groups (25–30%).
3.2.2. Zona Incerta (ZI). The graph in Figure 3(a) shows
the estimated number of Fos+ cells in the ZI of the four
experimental groups in the acute MPTP model. In the two-
hour survival period, there were no signiﬁcant diﬀerences
between the number of Fos+ cells in the diﬀerent groups
using an ANOVA test (F = 2.4; P>0.05). Using the Tukey-
Kramer test, no signiﬁcant diﬀerences in total number were
found between the saline group and saline-NIr (q = 3.4;
P>0.05), MPTP (q = 2.6; P>0.05), and MPTP-NIr
(q = 3.0; P>0.05) groups, between the saline-NIr group
and MPTP (q = 0.9; P>0.05), and MPTP-NIr (q = 0.5; P>
0.05) groups, nor between the MPTP and MPTP-NIr groups
(q = 0.4; P>0.05). In the six-day survival period, the MPTP4 Parkinson’s Disease
Fos+ cells
Saline
(a) (b)
ZIr
(c)
ZId
(d)
ZIv
(e)
ZIc
(f)
Figure 1: Fos+ cells in the STN (central region) and in the diﬀerent sectors of the ZI, namely, ZIr (a), ZId (b), ZIv (c), and ZIc (d). Fos
immunoreactivity was apparent in cell nuclei; cells were either strongly (black arrows) or weakly immunostained (white arrowheads). All
cases are from the saline group; patterns of immunostaining were similar in the other groups of both acute and chronic models. All ﬁgures
are of coronal sections; dorsal to top and lateral to right. Scale bar = 100µm.
group had many more Fos+ cells than the MPTP-NIr (35%),
saline-NIr (55%), and saline (75%) groups. Of particular
relevance was that the MPTP-NIr group had fewer Fos+ cells
than the MPTP group but more than the saline (65%) and
saline-NIr (35%) groups. Overall, these diﬀerences between
the groups were signiﬁcant using an ANOVA test (F =
43.3; P<0.0001). Using the Tukey-Kramer test, signiﬁcant
diﬀerences in total number were found between the MPTP
group and saline (q = 15.4; P<0.001), saline-NIr (q = 11.2;
P<0.001), and, notably, MPTP-NIr (q = 6.8; P<0.001)
groups. There were also signiﬁcant diﬀerences between the
saline group and the saline-NIr (q = 4.2; P<0.05) and
MPTP-NIr (q = 8.6; P<0.001) groups and between the
MPTP-NIr and Saline-NIr groups (q = 4.5; P<0.05).
The graph in Figure 3(b) shows the estimated number
of Fos+ cells in the ZI of the four groups in the chronic
MPTP model. The patterns of Fos+ cell number shown for
this model were similar to those described above for the
six-day survival acute model. The MPTP group had more
Fos+ cells than the MPTP-NIr (30%), saline-NIr (60%), and
saline (80%) groups. The MPTP-NIr group had fewer Fos+
cells than the MPTP group but many more cells than the
saline (70%) and saline-NIr (45%) groups. Overall, these
diﬀerences between the groups were signiﬁcant using an
ANOVA test (F = 66.8; P<0.0001). Using the Tukey-
Kramer test, signiﬁcant diﬀerences in total number were
found between the MPTP group and saline (q = 18.5; P<
0.001),saline-NIr(q = 14.4;P<0.001),andMPTP-NIr(q =
7.0;P<0.001)groups.Therewerealsosigniﬁcantdiﬀerences
between the MPTP-NIr group and the saline (q = 11.5;
P<0.001) and saline-NIr (q = 7.4; P<0.001) groups and
between the saline and saline-NIr groups (q = 4.1; P<0.05).
In summary, MPTP insult generated a substantial
increase in the number of Fos+ cells in both the STN and ZI,
and NIr treatment reduced this increase signiﬁcantly. These
changes were concurrent with changes in TH+ cell number
in the SNc in the acute model with six-day survival period
and chronic model [4, 5]. Unlike in the STN, there was a
signiﬁcant increase in the number of Fos+ cells in the ZI after
NIr treatment alone.
4. Distribution
4.1. Subthalamic Nucleus (STN). Figure 4 shows schematic
diagrams of the distribution of Fos+ cells in the STN
in the acute MPTP model with six-day survival period
(distributions were similar in the chronic model; in the two-
hour survival period, the distributions in all the groups were
similar to the saline group). In all groups, Fos+ cells tended
to be scattered across the nucleus, with no clear zone of
concentration. There were more Fos+ cells evident in the
MPTP-NIr and, in particular, the MPTP group than in the
saline controls (see above).
4.2. Zona Incerta (ZI). Figure 5 shows schematic diagrams
of the distribution of Fos+ cells in the ZI and its sectors
(rostral, dorsal, ventral, and caudal) of the diﬀerent groups
in the acute MPTP model with six-day survival period (as
with STN, distributions were similar in other models). In theParkinson’s Disease 5
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Figure 2: Graphs showing number of Fos+ c e l l si nt h eS T No ft h e
four groups in the acute (a) and chronic (b) MPTP mouse models.
Columns show the mean ± standard error of the total number of
c e l l si ne a c hg r o u p .I n( a )a n d( b ) ,† represents P<0.001 and ∧
represent P<0.01 signiﬁcant diﬀerence in cell number between
diﬀerent groups (using Tukey-Kramer multiple comparison test).
The symbols at the top of each column represents diﬀerences with
the saline group, while the symbols at the bottom of MPTP-NIr
group column represent diﬀerences with the MPTP group.
saline group, Fos+ cells were scattered sparsely across each
incertal sectors but with a tendency to concentrate in the
dorsal sector (Figure 5(a)). In the saline-NIr (Figure 5(b)),
MPTP (Figure 5(c)), and MPTP-NIr (Figure 5(d))g r o u p s ,
Fos+ cells were also found somewhat scattered, albeit in
higher numbers, across each of the sectors. In these groups,
the same concentration in the dorsal sector was evident.
In summary, the Fos+ cells in the STN showed no clear
pattern of topography across the nucleus, while in the ZI,
most cells were located in the dorsal sector.
5. Discussion
We had three main ﬁndings. First, unlike the STN, there
were many ZI cells that expressed the Fos protein after
NIr treatment. Second, in both the STN and ZI, MPTP
insult generated a substantial increase in the number of Fos+
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Figure 3: Graphs showing number of Fos+ cells in the ZI of the
four groups in the acute (a) and chronic (b) MPTP mouse models.
Columns show the mean ± standard error of the total number of
c e l l si ne a c hg r o u p .I n( a )a n d( b ) ,† represents P<0.001 and ∧
represent P<0.01 signiﬁcant diﬀerence in cell number between
diﬀerent groups (using Tukey-Kramer multiple comparison test).
The symbols at the top of each column represents diﬀerences with
the saline group, while the symbols at the bottom of MPTP-NIr
group column represent diﬀerences with the MPTP group.
cells. Finally, and most notably, NIr treatment reduced this
increase in STN and ZI Fos+ cell number after MPTP insult;
this reduction was concurrent with the neuroprotection of
TH+ cells in the SNc. These diﬀerences in Fos+ cell number
were evident in the longer-term survival periods (six days to
threeweeks)ofacuteandchronicmodels,indicatingthatNIr
(and MPTP) treatment had long lasting eﬀects on neuronal
function. Each of these issues will be explored below. First, a
comparison with previous studies will be considered.
5.1. Comparison with Previous Studies. To the best of our
knowledge, there has been no other study that has examined
Fos expression in the STN and ZI, nor indeed the brain,
after NIr treatment. Several previous studies, using diﬀerent
methods and animal models of Parkinson’s disease, have
reported on the patterns of cell activity in the STN and ZI.
These studies have used either metabolic markers and/or6 Parkinson’s Disease
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Figure 4: Schematic diagrams of the distribution of Fos+ cells in the diﬀerent sectors of the STN in the saline (a), saline-NIr (b), MPTP
(c) and MPTP-NIr groups. These maps are from the acute model with six-day survival period (similar patterns were evident in the chronic
model; in the acute model with two-hour survival period, the distribution of cells was similar to the saline cases shown here). Each black
circle represents one cell. These maps were taken from coronal sections similar to the plates of the mouse atlas (numbers in italics [1]) shown
in (e).
electrophysiological methods in 6-OHDA-lesioned rats [10,
11, 13]o rM P T P - t r e a t e dm o n k e y s[ 12]. We conﬁrm these
previous reports of an increase in cell activity in STN and
ZI by using Fos immunocytochemistry in MPTP-treated
mice. It should be noted that somewhat diﬀerent results
have been reported in 6-OHDA-lesioned rats using Fos
immunocytochemistry in these nuclei. In these studies, very
few Fos+ cells were seen in the STN [24]o rZ I[ 25]a f t e r6 -
OHDA lesion. The reason for this diﬀerence in our studies
is not entirely clear, but it may be related to the diﬀerent
animalsused(6-OHDAversusMPTP)—andtherehavebeen
many reports of dissimilar results using the diﬀerent models
[26]—together with the location of the 6-OHDA injection
site. In the previous studies, 6-OHDA was injected into the
medial forebrain bundle which lies immediately adjacent to
the STN and ZI. There could have been some spread of
the 6-OHDA toxin from the injection site into the adjacent
STN and ZI, and this may have inﬂuenced the expression
of Fos in these cases. Indeed, in cases where 6ODHA was
injected directly into the SNc, a region well away from the
STN and ZI, an increase in cellular STN and ZI activity was
apparent [10–13]. Perhaps 6-OHDA injections into the SNc
or striatum, regions well away from the STN and ZI, may
generate results similar to ours seen here in MPTP-treated
mice.
5.2. NIr Treatment Induced Fos Expression in Zona Incerta.
One of our most striking, and least expected, ﬁndings was
of an increase in Fos expression within the ZI but not
the STN after the application of NIr treatment alone. Two
mechanisms for this increase in expression can be suggested.
First,NIrcouldhaveactivatedanexcitatoryaﬀerentpathway,
one that terminates in the ZI and not the STN, triggering Fos
expression. Such a pathway was likely to originate from the
superior colliculus, which has a very heavy projection to the
ZI (in particular to its dorsal sector), but not the STN [27–
29]. The superior colliculus receives a large and direct input
from the retina, whose cells may have been activated directly
by NIr. Further, the retina has a direct, albeit very small,
input to the ZI but not to the STN [27, 29]. This small input,
through an extensive network of inter-ZI connections [29],
may have contributed to the Fos expression in the ZI as well.
Second, NIr could have activated directly the mitochondria
within the ZI cells themselves, inducing Fos expression. The
ZI cells may have been more susceptible to photoacceptor
(cytochrome oxidase) activation than the cells in the STN.
It remains to be determined which other cell groups in the
central nervous system are activated by NIr treatment alone,
and how they may relate to the activated ZI cells described
here.Parkinson’s Disease 7
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Figure 5: Schematic diagrams of the distribution of Fos+ cells in the diﬀerent sectors of the STN in the saline (a), saline-NIr (b), MPTP
(c) and MPTP-NIr groups. These maps are from the acute model with six-day survival period (similar patterns were evident in the chronic
model; in the acute model with two-hour survival period, the distribution of cells was similar to the saline cases shown here). Each black
circle represents one cell. These maps were taken from coronal sections similar to the plates of the mouse atlas (numbers in italics [1]) shown
in (e).
5.3. Fos Expression after MPTP Treatment. We report that
MPTP insult induced Fos expression in the STN and ZI. In
fact, the MPTP group had more Fos+ cells in both nuclei
than any one of the other groups. This activation was likely
to manifest after the loss of SNc dopaminergic cells caused
by the MPTP [10–13]. For the ZI, it receives a very weak
direct projection from the SNc, hence the activation was
likely to occur indirectly via, for example, the PpT, which is
overactive in parkinsonian cases and has heavy projections
to the ZI [29]. For the STN, it receives a more substantial
SNc projection, together with heavy projections from the
PpT [27, 28], and hence these projections may have both
contributed to the Fos expression in this nucleus.
Hence, there appear to be two very diﬀerent triggers or
mechanisms that generated the Fos expression. In the MPTP
group,FosexpressioninboththeSTNandZIwaslikelytobe
induced after a loss of dopaminergic cells from the SNc (and
overactive PpT projections), while in the saline-NIr group,
a group that had no loss of SNc cells, Fos expression in the
ZI may have been induced by pathways stimulated by retinal
aﬀerents (via the superior colliculus) after the NIr treatment.
5.4. NIr Treatment Reduced Abnormal Fos Expression Induced
by MPTP Insult: A Long-Lasting Eﬀect. Our results showed
that neuroprotection or saving of dopaminergic cells in the
SNc from MPTP toxicity by NIr treatment [4, 5]r e s u l t e d
in a reduction of the abnormal overactivity (increase in Fos
expression) in the STN and ZI. There were fewer Fos+ cells in
theMPTP-NIrcomparedtotheMPTPgroup.Thenumberof
cells in the MPTP-NIr group was, however, still higher than
in the saline-NIr (30–45%) and saline (60%) control groups,
indicating that the NIr treatment did not reduce entirely
the abnormal activity generated by the MPTP toxin; if it
did, then the MPTP-NIr and saline-NIr groups would have
had very similar cell numbers. Nevertheless, the reduction
was clear and signiﬁcant in the MPTP-NIr group and it
may represent a reversal, at least in part, of the abnormal
circuits generated by MPTP. It remains to be determined
whether these changes in neuronal activity by NIr treatment
are evident in behavioural and clinical studies.
IntheMPTPandMPTP-NIrgroupsinboththeSTNand
ZI,andsaline-NIrgroupintheZI,thereweremanyFos+ cells
in the acute model with six-day survival and chronic model
(three weeks survival). Previous studies have indicated that
although the peak of Fos expression occurs about two hours
after some forms of stimulation (e.g., peripheral noxious
[17, 23]), it may still be present weeks or months after
others (e.g., 6-OHDA lesion [25]). We show here that MPTP8 Parkinson’s Disease
treatment had a long-term (six days to three weeks) impact
on Fos expression, presumably due to the triggering and
maintenance of abnormal basal ganglia circuitry (see above).
Further, we show that even after minimal exposure, NIr
treatment generated longer-term eﬀects (six days to three
weeks) on cell activity also. This ﬁnding is most encouraging
when considering therapeutic use. In this context, it has been
shown recently that patients suﬀering from depressive illness
show improved depression and anxiety rating scales up to a
month after a single dose of NIr treatment [20].
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